Dyadic International Inc. (NASDAQ:DYAI) announced 2024 results and listed a number of accomplishments that will bring both product and grant revenue in the next months. We are most excited about ...

Please contact [email protected], if you would like to schedule a meeting with Dyadic management. About Dyadic International, Inc. Dyadic International, Inc., is a biotechnology company focused ...

Q4 2024 Earnings Call Transcript March 26, 2025 Dyadic International, Inc. misses on earnings expectations. Reported EPS is $-0.05 EPS, expectations were $-0.04. Operator: Good evening. And welcome to ...

Thank you, Ping. Welcome everyone and thank you for joining Dyadic's full year 2024 conference call. We're excited to share how our strategic focus on near-term product commercialization and ...

Dyadic International Inc (NASDAQ:DYAI) reported strong revenue performance in 2024, including $1.9 million in milestone and license payments. The company is advancing its dual-track strategy by ...

Reagent Proteins & DNA/RNA Enzymes DNase1 (RNase-free): Dyadic's DNASe-1 product designed for use in molecular diagnostics, biopharma, and other industries is progressing toward commercial ...